Clinical Trials Logo

Recurrent Mantle Cell Lymphoma clinical trials

View clinical trials related to Recurrent Mantle Cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06300528 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well pemigatinib works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Pemigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT05936229 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Start date: April 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Interferon beta-1a is in a class of medications called immunomodulators. It works by protecting the lining of blood vessels, and preventing brain inflammation. Giving FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in patients receiving CD19 CAR T-cell therapy with recurrent or refractory B-cell malignancies.